Earnings Analysis of Hologic, Inc.(NASDAQ:HOLX) and Incyte Corporation(NASDAQ:INCY)

0
5

Hologic, Inc. (HOLX) will report its next earnings on Feb 06 AMC. The company reported the earnings of $0.58/Share in the last quarter where the estimated EPS by analysts was $0.58/share. The difference between the expected and actual EPS was $0/share, which represents an Earnings surprise of 0%.

Many analysts are providing their Estimated Earnings analysis for Hologic, Inc. and for the current quarter 18 analysts have projected that the stock could give an Average Earnings estimate of $0.57/share. These analysts have also projected a Low Estimate of $0.56/share and a High Estimate of $0.6/share.

In case of Revenue Estimates, 17 analysts have provided their consensus Average Revenue Estimates for Hologic, Inc. as 811.33 Million. According to these analysts, the Low Revenue Estimate for Hologic, Inc. is 805.3 Million and the High Revenue Estimate is 823.07 Million. The company had Year Ago Sales of 791.1 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for HOLX to be 3.6%. They are projecting Next Quarter growth of 9.43%. For the next 5 years, Hologic, Inc. is expecting Growth of 8.33% per annum, whereas in the past 5 years the growth was 7.62% per annum.

Some buy side analysts are also providing their Analysis on Hologic, Inc., where 2 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 4 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Hologic, Inc. might touch $50 high while the Average Price Target and Low price Target is $45.06 and $39 respectively.

Hologic, Inc. closed its last trading session at $42.08 with the gain of 1.14%. The Market Capitalization of the company stands at 12.08 Billion. The Company has 52-week high of $45.17 and 52-week low of $35.10. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 5.55% where SMA50 and SMA200 are 3.59% and 6.64% respectively. The Company Touched its 52-Week High on 12/04/18 and 52-Week Low on 05/03/18.

The Relative Volume of the company is 0.79 and Average Volume (3 months) is 2.46 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 16.28.

The company shows its Return on Assets (ROA) value of -1.5%. The Return on Equity (ROE) value stands at -4.2%. While it’s Return on Investment (ROI) value is -5.6%.

While looking at the Stock’s Performance, Hologic, Inc. currently shows a Weekly Performance of 11.18%, where Monthly Performance is 0.42%, Quarterly performance is 2.93%, 6 Months performance is 2.38% and yearly performance percentage is -3.75%. Year to Date performance value (YTD perf) value is 3.55%. The Stock currently has a Weekly Volatility of 2.62% and Monthly Volatility of 3.05%.

Incyte Corporation (INCY) will report its next earnings on Jan 29 BMO. The company reported the earnings of $0.38/Share in the last quarter where the estimated EPS by analysts was $0.4/share. The difference between the expected and actual EPS was $-0.02/share, which represents an Earnings surprise of -5%.

Many analysts are providing their Estimated Earnings analysis for Incyte Corporation and for the current quarter 14 analysts have projected that the stock could give an Average Earnings estimate of $0.48/share. These analysts have also projected a Low Estimate of $0.2/share and a High Estimate of $0.61/share.

In case of Revenue Estimates, 16 analysts have provided their consensus Average Revenue Estimates for Incyte Corporation as 489.41 Million. According to these analysts, the Low Revenue Estimate for Incyte Corporation is 456.8 Million and the High Revenue Estimate is 540.09 Million. The company had Year Ago Sales of 444.16 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for INCY to be 2100%. They are projecting Next Quarter growth of 3700%. For the next 5 years, Incyte Corporation is expecting Growth of 99.73% per annum, whereas in the past 5 years the growth was 67.19% per annum.

Some buy side analysts are also providing their Analysis on Incyte Corporation, where 3 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 2 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Incyte Corporation might touch $102 high while the Average Price Target and Low price Target is $84.29 and $70 respectively.

Incyte Corporation closed its last trading session at $73.7 with the gain of 1.93%. The Market Capitalization of the company stands at 15.97 Billion. The Company has 52-week high of $97.24 and 52-week low of $57.00. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 14.3% where SMA50 and SMA200 are 14.45% and 10.81% respectively. The Company Touched its 52-Week High on 01/24/18 and 52-Week Low on 12/24/18.

The Relative Volume of the company is 1.07 and Average Volume (3 months) is 1.71 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 35.62.

The company shows its Return on Assets (ROA) value of -4.6%. The Return on Equity (ROE) value stands at -6.4%. While it’s Return on Investment (ROI) value is -14.8%.

While looking at the Stock’s Performance, Incyte Corporation currently shows a Weekly Performance of 10.37%, where Monthly Performance is 14.83%, Quarterly performance is 14.69%, 6 Months performance is 6.89% and yearly performance percentage is -21.99%. Year to Date performance value (YTD perf) value is 18.13%. The Stock currently has a Weekly Volatility of 4.29% and Monthly Volatility of 4.56%.

SHARE